Genetic Technologies (AU:GTG) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Rhythm Biosciences Ltd has acquired the Genetype genetic risk assessment business, enhancing its oncology portfolio with an immediate revenue stream and growth potential. This strategic acquisition allows Rhythm to leverage Genetype’s expertise and expand its market presence in both Australia and the US. The integration of Genetype’s technology and team is expected to drive accelerated commercial growth and diversification.
For further insights into AU:GTG stock, check out TipRanks’ Stock Analysis page.
